isoniazid has been researched along with Bowel Diseases, Inflammatory in 3 studies
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Isoniazid (INH) prophylaxis is recommended for the prevention of tuberculosis (TB) reactivation before or/and during initiation of treatment with tumour necrosis factor antagonists (anti-TNF agents)." | 3.91 | Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy? ( Akyuz, F; Besisik, F; Cagatay, T; Cavus, B; Demir, K; Evirgen, S; Gulluoglu, M; Iliaz, R; Karaca, C; Kaymakoglu, S; Keskin, M; Koksalan, K; Onder, S; Ormeci, A; Soyer, OM, 2019) |
| "Data from regular monitoring for latent tuberculosis infection [LTBI] during biologic treatment are lacking." | 1.48 | A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases. ( Chen, M; Hung, E; Ip, M; Lee, CK; Lui, G; Ng, SC; Tam, LS; Tang, W; Wong, SHV; Wu, JC, 2018) |
| " ChP is safe in IBD patients even in those taking concomitant, potentially hepatotoxic drugs." | 1.35 | Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. ( Araméndiz, R; Beltrán, B; Cabré, E; Cabriada, JL; Domènech, E; Gassull, MA; Ginard, D; Gisbert, JP; Hinojosa, J; Mañosa, M; San Román, AL; Saro, C; Zabana, Y, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, CK | 1 |
| Wong, SHV | 1 |
| Lui, G | 1 |
| Tang, W | 1 |
| Tam, LS | 1 |
| Ip, M | 1 |
| Hung, E | 1 |
| Chen, M | 1 |
| Wu, JC | 1 |
| Ng, SC | 1 |
| Akyuz, F | 1 |
| Cavus, B | 1 |
| Iliaz, R | 1 |
| Soyer, OM | 1 |
| Ormeci, A | 1 |
| Evirgen, S | 1 |
| Onder, S | 1 |
| Koksalan, K | 1 |
| Keskin, M | 1 |
| Karaca, C | 1 |
| Demir, K | 1 |
| Gulluoglu, M | 1 |
| Cagatay, T | 1 |
| Besisik, F | 1 |
| Kaymakoglu, S | 1 |
| Zabana, Y | 1 |
| Domènech, E | 1 |
| San Román, AL | 1 |
| Beltrán, B | 1 |
| Cabriada, JL | 1 |
| Saro, C | 1 |
| Araméndiz, R | 1 |
| Ginard, D | 1 |
| Hinojosa, J | 1 |
| Gisbert, JP | 1 |
| Mañosa, M | 1 |
| Cabré, E | 1 |
| Gassull, MA | 1 |
3 other studies available for isoniazid and Bowel Diseases, Inflammatory
| Article | Year |
|---|---|
A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases.
Topics: Adult; Antirheumatic Agents; Antitubercular Agents; Biological Therapy; Female; Gastrointestinal Age | 2018 |
Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy?
Topics: Adult; Aged; Antitubercular Agents; Chemoprevention; Female; Humans; Inflammatory Bowel Diseases; In | 2019 |
Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antibiotic Prophylaxis; Antitubercular Agents; Comorbidity; Fe | 2008 |